Breakdown | |||||
TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
18.59M | 0.00 | 22.60M | 24.89M | 17.38M | 11.35M | Gross Profit |
9.30M | 0.00 | 11.54M | 11.49M | 8.80M | 5.66M | EBIT |
-6.78M | 0.00 | -19.65M | -10.83M | -10.77M | -5.84M | EBITDA |
-2.97M | 0.00 | -12.82M | -6.25M | -2.93M | -4.80M | Net Income Common Stockholders |
-9.39M | 0.00 | -18.70M | -11.38M | -6.92M | -4.80M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
754.00K | 0.00 | 3.19M | 6.60M | 9.88M | 2.41M | Total Assets |
35.97M | 0.00 | 41.73M | 61.52M | 61.81M | 25.98M | Total Debt |
12.26M | 12.12B | 10.57M | 9.75M | 10.14M | 2.72M | Net Debt |
11.51M | 12.12B | 7.38M | 3.15M | 256.00K | 312.00K | Total Liabilities |
22.05M | 23.30B | 22.92M | 26.01M | 27.77M | 8.49M | Stockholders Equity |
13.91M | 12.28B | 18.81M | 35.51M | 34.04M | 17.49M |
Cash Flow | Free Cash Flow | ||||
-3.37M | 0.00 | -3.84M | -9.08M | -5.00M | -7.58M | Operating Cash Flow |
-2.69M | 0.00 | -2.21M | -7.14M | -3.50M | -5.76M | Investing Cash Flow |
-679.00K | 0.00 | -1.62M | -1.94M | -13.17M | 9.46M | Financing Cash Flow |
1.57M | 0.00 | 428.00K | 5.79M | 24.15M | -2.94M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
59 Neutral | $21.46M | ― | -65.35% | ― | -20.78% | 49.22% | |
53 Neutral | $5.23B | 3.23 | -44.27% | 2.82% | 16.82% | 0.11% | |
47 Neutral | $15.52M | ― | -58.71% | ― | -79.66% | -141.87% | |
39 Underperform | $11.70M | ― | -737.89% | ― | -99.36% | 63.06% | |
38 Underperform | $7.92M | ― | -60.06% | ― | ― | 8.99% | |
31 Underperform | $14.86M | ― | -202.81% | ― | ― | 64.01% | |
23 Underperform | $4.48M | ― | -439.23% | ― | ― | 56.73% |
On May 29, 2025, Streamline Health Solutions entered into a merger agreement with MDaudit, under which MDaudit will acquire all outstanding shares of Streamline for $5.34 per share in cash, representing a 138% premium over Streamline’s closing price on May 28, 2025. This merger aims to combine Streamline’s pre-bill integrity solutions with MDaudit’s billing compliance and revenue integrity platform, enhancing the ability to unify data silos and drive coordinated actions across the revenue cycle continuum, ultimately improving financial stability for healthcare organizations.
The most recent analyst rating on (STRM) stock is a Buy with a $22.50 price target. To see the full list of analyst forecasts on Streamline Health Solutions stock, see the STRM Stock Forecast page.